Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pneumagen Targeting The Human Glycome To Block Viral Entry

COVID-19 Among Potential Uses

Executive Summary

Emerging Company Profile: UK biotech Pneumagen expects to enter clinical studies in 2021 with a potential first-in-class glycan-targeted protein for preventing respiratory tract infections.

You may also be interested in...



Coronavirus Update: UK Trials Six Candidates

The UK Government’s Therapeutics Taskforce has identified a number of drug candidates that could be used to treat COVID-19 and the first candidate is ready to enter clinical trials.

Denali Sees Some Early Progress With Fusion Protein For Hunter Syndrome

Denali Therapeutics has reported promising early clinical data in Hunter syndrome for its fusion protein, DNL310, an investigational agent that crosses the blood-brain barrier and is expected to address disease-associated CNS effects; however, some biomarker data disappointed, and there are potential competitors also under development.

Ipsen Strengthens Early Clinical Pipeline With IRLAB’s Mesdepotem For Levodopa-Induced Dyskinesia

Ipsen has gained worldwide development and commercialization rights to IRLAB’s dopamine D3 antagonist, mesdepotem, in levodopa-induced dyskinesia in Parkinson’s disease.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel